MA-EXAGRID
28.5.2019 17:41:10 CEST | Business Wire | Press release
ExaGrid ® , a leading provider of intelligent hyperconverged storage for backup, today announced that Physicians’ Reciprocal Insurers (PRI) uses ExaGrid disk-based backup systems to significantly increase data protection with secure backups.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190528005580/en/
PRI is a leading provider of professional liability insurance for physicians and medical facilities. As the second largest medical malpractice insurer in New York State and one of the top ten in the U.S., PRI is recognized as one of the most respected names in its field.
PRI replaced its previous system with ExaGrid and Veeam after its IT staff spent too much time troubleshooting backup issues. Al Villani, PRI’s senior system administrator said, “Veritas NetBackup wasn’t set up to send us any kind of alerts if there was an issue, so we had to log in and look through it, which was a lot of manual work. Our calls to Symantec support were sent offshore right away, and by the time they got back to us, we had usually found the solution by searching online. Veritas eventually reacquired NetBackup, but the support never improved.”
ExaGrid solved backup issues PRI had struggled with, including:
- Storage capacity issues
- Backups that exceeded window, slowing company-wide systems during workday
- Time-consuming backup management
- Complicated offsite storage
The security of data storage in the insurance industry has been moving toward stricter regulation, so PRI looked for a solution that would help keep the company ahead of the curve. “The insurance claims we process contain sensitive information, such as birth dates and Social Security numbers—even the tape we used was encrypted, the cases we stored them in were locked, and Iron Mountain had to sign for them—the state regulations are pretty thorough when it comes to security. Many solutions don’t offer encryption or the ability to encrypt at rest like ExaGrid does,” said Villani.
A major issue that PRI faced was that its backups took days and slowed the entire system down, impacting workflow. “Our weekly full backup used to run from Saturday morning at 2:00 a.m. all the way into Tuesday afternoon. Every Monday, users would be calling in and asking why the system was so slow. Now, our weekly full takes just three hours! We thought something was broken the first time we used ExaGrid, so we called our support engineer who confirmed that everything ran correctly. It’s totally incredible! Working with our [ExaGrid] support engineer has been a saving grace. Managing backups had been a nightmare at times, but switching to ExaGrid has been a dream come true. We’re saving about 25-30 hours a week on managing backups. The ExaGrid system doesn’t need a lot of babysitting, and our support engineer is available whenever we need help with any issue.”
As an insurance company, PRI has a complex retention policy for its data. “We keep five weeks of daily backups, eight weeks of weekly backups, a year’s worth of monthly backups onsite, and one yearly onsite with seven yearlies offsite, as well as offsite storage for infinite fiscals and monthly backups,” said Villani. “We were skeptical at first that an ExaGrid system could handle that amount of storage, but the engineers sized everything really well and ExaGrid guaranteed the sizing would work for two years, and that if we needed to add another appliance, they would supply it. Seeing that in writing was pretty impressive!”
Read the complete PRI customer success story to learn more about the company’s experience using ExaGrid.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
About ExaGrid
ExaGrid provides intelligent hyperconverged
storage for backup with data deduplication, a unique landing zone, and
scale-out architecture. ExaGrid’s landing zone provides for the fastest
backups, restores, and instant VM recoveries. Its scale-out architecture
includes full appliances in a scale-out system and ensures a
fixed-length backup window as data grows, eliminating expensive forklift
upgrades. Visit us at exagrid.com
or
connect with us on LinkedIn
.
See what our customers have to say about their own ExaGrid experiences
and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005580/en/
Contact:
Stacey Foster ExaGrid sfoster@exagrid.com 508-898-2872 x0248
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom